Blood Substitutes

(redirected from Oxycyte)

Blood Substitutes

 

plasma substitutes, agents used for therapeutic purposes instead of blood transfusion, for the dilution of banked whole blood, and in cases of shock, blood loss, burn, anemias, and purulent septic diseases.

The injection of blood substitutes is often combined with the transfusion of donor blood. Blood substitutes are divided, according to action, into antishock, detoxification, and parenteral-feeding preparations. Many blood substitutes have compound effects.

The most commonly used antishock preparations are polyglucin (dextran), polyvinylpyrrolidone, and gelatin preparations. Polyglucin is a polymer of glucose that is synthesized by the bacteria Leuconostoc mesenteroides. Soviet polyglucin does not decrease the function of the coagulation system. Polyvinylpyrrolidone is a polymer that consists of 250 to 300 chains of vinylpyrrolidone. Gelatinol, which is produced from modified gelatin, is used in extracorporeal blood circulation (in heart operations).

Detoxification blood substitutes are represented by preparations of low-molecular-weight polyvinylpyrrolidone (molecular weight, 10,000–12,000). The preparations (in particular, Gemodez) contain 6-percent low-molecular-weight polyvinylpyrrolidone and saline or glucose solutions. They are highly effective in detoxification with radiation sickness and burn diseases. Low-molecular-weight polyvinylpyrrolidone has a diuretic effect and reduces stasis in the capillaries. Protein preparations also have a detoxifying effect.

The preparations used in parenteral feeding include native protein products (plasma and albumin) and protein hydrolysates (casein hydrolysate of the Central Order of Lenin Scientific Research Institute of Hematology and Blood Transfusion, hydroly-sate L-103, and aminopeptide). These are used to treat weakened postoperative patients, burns of the esophagus, hypoproteinemic states of various etiology, and burn diseases.

Fatty emulsions (from 10 to 20 percent fat) from cottonseed oil (Lipofundinum in the Federal Republic of Germany; Lipomulum in the USA) and soybean oil (Intralipidum in Sweden) are also manufactured as parenteral substitutes. Lipomaiz, made from corn oil at the Leningrad Blood Transfusion Institute, contains 10 percent fat. These emulsions are used parenterally to increase the body’s energy resources. The combined use of hydrolysates and fat emulsions is recommended.

REFERENCES

Filatov, A. N., Z. A. Chaplygina, and M. E. Depp. Belkovye gidrolizaty. [Leningrad] 1968.
Petrov, I. R., V. A. Bondina, and E. A. Senchilo. Plazmozameshchaiushchie rastvory pri lechenii krovopoteri i shoka. Leningrad, 1969.
Spravochnik po krovezameniteliam i preparatam krovi. Edited by A. I. Burnazian. Moscow, 1969.
References in periodicals archive ?
The Company's Oxycyte oxygen carrier product is a perfluorocarbon emulsified with water and a surfactant, which is provided to the patient intravenously.
Oxygen plans to use the proceeds from the transaction to further its clinical trials and efforts to obtain regulatory approval of Oxycyte([R]), develop its product candidates, including dermatologic indications using its topical gel, support manufacturing of Oxycyte, for research and development and for general corporate purposes, including working capital and potential acquisitions.
The decrease in research and development expenses for the three months ended October 31, 2011 was driven primarily by a reduction in compensation and contract research organization (CRO) costs; partially offset by an increase in consulting costs and Oxycyte PFC development costs.
His extensive research and knowledge in oxygen therapies eventually led to the creation of oxycyte, which is a third generation oxygen carrier designed to enhance oxygen delivery to damaged tissues.
The DERMACYTE skin care line uses our oxycyte technology (an oxygen carrier) to deliver oxygen to tissues, such as skin.
Durham, NC) has submitted a patent application for a new invention that uses Oxycyte perfluorocarbon to deliver oxygen as a first aid treatment for victims of heart attacks and strokes.
DERMACYTE Oxygenating Eye Complex is an enriched oxygen emollient developed by the makers of oxycyte technology (an oxygen carrier).
Levosimendan is primarily for use in patients with ADHF and Low Cardiac Output Syndrome (LCOS), while Oxycyte is currently being evaluated for the treatment of traumatic brain injury (TBI), decompression illness (DCI) aka "the bends" and stroke.
Currently we are working diligently to resume our TBI trials in Israel and Switzerland; we are collaborating with Aurum Biosciences to develop better MRI diagnostics for stroke patients; and we continue to provide Oxycyte to the U.
Oxycyte (Oxygen Biotherapeutics) Perftoran (Perftoran) PHER-O2 (Sanguine Corp.
Army Institute of Surgical Research (USAISR) at Fort Sam Houston Texas to explore the potential effects of OBI's proprietary perfluorocarbon-based emulsion, Oxycyte, on platelet function and blood hemostasis.
Oxygen stated that it is currently enrolling patients outside of the US in a Phase II-b study to evaluate the safety and tolerability of Oxycyte in patients with severe non-penetrating traumatic brain injury (STOP-TBI).